RankAlpha logo
Back to Rankings

LGND

LigandB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
LGND vs peer average
52/100
LGND vs. peer average (B vs. B)
Grade spread
A 1 · B 5 · C 2
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RPRX is the first available peer comparator.

Royalty Pharma remains the clearest public model peer for diversified biopharma royalty cash-flow valuation, even though it operates at much larger scale.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRPRXRoyalty
LGND
Ligand
RPRX
Royalty
Grade
B
B
Momentum
72
80
Value
58
61
Sentiment
42
34
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs RPRX

LGND / RPRX
Grade Position
In line
LGND vs. peer average (B vs. B)
52/100
Momentum
72
RPRX
Value
58
RPRX
Sentiment
42
LGND

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs LGND
1
RPRX
RPRX
B
80/100
Even
2
XOMA
XOMA
B
80/100
Even
3
CAI
Caris Life Sciences Inc Common
N/A
-
-
4
NNNN
Anbio Biotechnology Class A Common
N/A
-
-
5
DNTH
Dianthus Therapeutics Inc Common
B
80/100
Even
RPRX is the first peer returned for this comparison set.